Ralimetinib

Generic Name
Ralimetinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H29FN6
CAS Number
862505-00-8
Unique Ingredient Identifier
73I34XW4HD
Background

Ralimetinib has been used in trials studying the treatment of Postmenopausal, Advanced Cancer, Adult Glioblastoma, Fallopian Tube Cancer, and Metastatic Breast Cancer, among others.

Associated Conditions
-
Associated Therapies
-

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

First Posted Date
2016-08-09
Last Posted Date
2018-12-14
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
9
Registration Number
NCT02860780
Locations
🇺🇸

Carolinas Medical Center, Charlotte, North Carolina, United States

🇺🇸

Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States

🇩🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany

© Copyright 2024. All Rights Reserved by MedPath